• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CUV
Click for more information
1.36% $13.37

CLINUVEL PHARMACEUTICALS LIMITED - Charts / Financials

Market Cap $669.5M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical... Clinuvel Pharmaceuticals Limited is an Australia-based global specialty pharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).More

refresh Created with Sketch. REFRESH
Last update - 15.59pm 23/08/2024 (20 minute delay) ?
Day
Open $13.19   Day High $13.59   Day Low $13.13
Daily Volume 88202
Bids   Sellers
Number Price Volume   Number Price Volume
1 $13.31 606   1 $13.51 282

Directors & Senior Management

Dr. Philippe J. Wolgen Chief Executive Officer, Managing Director, Executive Director
Mr. Peter Vaughan Chief Financial Officer
Dr. Dennis J. Wright Chief Scientific Officer
Ms. Claire Newstead-Sinclair Company Secretary
Prof. Jeffrey V. Rosenfeld Non-Executive Chairman of the Board
Dr. Karen A. Agersborg Non-Executive Independent Director
Sir Andrew Likierman Non-Executive Independent Director
Mrs. Brenda Mary Shanahan Non-Executive Independent Director
Mrs. Susan E. Smith Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
$13.37 		Change
0.180(1.36%) 		Mkt cap ! $669.5M
Open High Low Value Volume
$13.19 $13.59 $13.13 $1.181M 88.20K

Buyers (Bids)

No. Vol. Price($)
1 606 $13.31
 

Sellers (Offers)

Price($) Vol. No.
$13.51 282 1
View Market Depth
Last trade - 16.10pm 23/08/2024 (20 minute delay) ?
Last
$13.37 		  Change
0.180 ( 1.23 %)
Open High Low Volume
$13.23 $13.61 $13.18 17074
Last updated 15.59pm 23/08/2024 ?

Top Stories

Dale Gillham's weekly wrap: responding to a weak iron ore price with investing decisions

Given the recent fall in iron ore prices below the $100 mark, now might be the time to buy into specialised stocks in the materials sector.
Noronex kicks off EM survey at Humpback, Namibia – part of South32's earn-in deal to access Kalahari Copper Belt Noronex Limited (ASX:NRX) has kicked off a gravity EM survey at the Damara project in Namibia – part of its earn-in deal with South32.
How flooding did Strategic Energy Resources a favour: Four holes down in 'redesigned' gold & copper campaign Strategic Energy Resources is 4 holes into a 40-hole RC drill campaign at its Achilles 1 copper-gold target in the Cobar Basin of NSW.
Raiden gears up for exploration in final quarter of 2024 Raiden Resources Ltd - which is exploration for a multiplicity of minerals in the Pilbara region of WA - is looking ahead to a busy schedule.
Reporting wrap: Inghams, Accent, Mayne Pharma Inghams Group Ltd, Accent Group Ltd and Mayne Pharma Group Ltd all reported final year results for the 2024 fiscal year.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.